H. pylori (Antigen or Antibody)

← Back to Lab Reference Library

Category: Gut & Immune  |  Also known as: Helicobacter pylori, H. pylori Stool Antigen, H. pylori Antibody Test, Urea Breath Test

1. What This Test Measures

Helicobacter pylori testing detects infection by the gram-negative spiral bacterium that colonizes the gastric mucosa of approximately 44% of the global population, making it the single most prevalent chronic bacterial infection worldwide. H. pylori survives in the acidic stomach environment through a remarkable biochemical strategy: it produces urease, an enzyme that converts urea to ammonia and carbon dioxide, creating a local alkaline microenvironment that neutralizes gastric acid around the organism and enables it to penetrate the protective mucus layer overlying the gastric epithelium.

Once established, H. pylori induces chronic active gastritis in virtually every colonized individual. The majority of infected people carry the infection asymptomatically for decades; approximately 10 to 15% develop peptic ulcers; 1 to 3% develop gastric adenocarcinoma; and a small proportion develop MALT (mucosa-associated lymphoid tissue) lymphoma. Beyond gastric consequences, H. pylori has significant systemic effects through its impact on gastric acid production, B12 absorption, iron absorption, and its induction of systemic inflammatory and autoimmune responses.

Four testing modalities are available, each with distinct clinical applications: the stool antigen test (SAT), the urea breath test (UBT), serum antibody testing (IgG, IgM, IgA), and endoscopic biopsy with rapid urease test or culture. The choice of test depends on whether the clinical question is diagnosing active infection, confirming eradication after treatment, or screening in a population-level context.

2. Test Selection and Interpretation

Test	Result Meaning	Best Used For	Key Limitation
Stool Antigen Test (SAT)	Positive = active infection; Negative = infection absent or below detection	Diagnosing active infection; confirming eradication post-treatment (gold standard for both)	False negative if tested within 2 weeks of PPI use or within 4 weeks of antibiotic use; collect at least 4 weeks post-treatment
Urea Breath Test (UBT)	Positive = active urease-producing H. pylori; Negative = no active infection	Diagnosing active infection; confirming eradication; preferred in children	Same preparation requirements as SAT; radioactive (13C-UBT) or mildly radioactive (14C-UBT) isotope required; less widely available than SAT
Serum IgG Antibody	Positive = past or current infection; Negative = no prior exposure (or failed antibody response)	Epidemiological screening; confirming prior exposure; initial workup when PPIs cannot be stopped	Cannot distinguish active from resolved infection; remains positive 12 to 18 months after eradication; cannot confirm eradication
Endoscopic Biopsy + Rapid Urease Test (RUT)	Positive = active H. pylori at biopsy site; histology shows chronic active gastritis	Patients undergoing endoscopy for other indications; assessing atrophy, intestinal metaplasia, or MALT	Sampling error possible if biopsies not taken from antrum and body; requires endoscopy

PPI use within 2 weeks before testing produces significant false-negative rates on SAT and UBT by suppressing H. pylori metabolic activity below detection thresholds. Ideally discontinue PPIs for 2 weeks before non-endoscopic testing. When PPIs cannot be safely discontinued, serum IgG antibody testing is the only reliable non-endoscopic option, with the understanding that it cannot confirm eradication.

3. Systemic Consequences Beyond the Stomach

• Vitamin B12 deficiency: H. pylori-induced chronic atrophic gastritis progressively destroys the parietal cells that produce both gastric acid and intrinsic factor; intrinsic factor is essential for ileal B12 absorption; long-standing H. pylori infection is a major but underrecognized cause of B12 deficiency producing megaloblastic anemia, peripheral neuropathy, cognitive decline, and elevated homocysteine
• Iron deficiency anemia: H. pylori impairs iron absorption through multiple mechanisms: gastric acid reduction decreases conversion of dietary ferric iron to the absorbable ferrous form; H. pylori itself consumes iron as a nutrient for its own growth; the chronic gastric inflammation increases hepcidin production, sequestering iron in macrophages; iron-deficiency anemia resistant to supplementation that resolves after H. pylori eradication is a well-documented and frequently missed clinical scenario
• Elevated cardiovascular risk: H. pylori infection is associated with elevated CRP, fibrinogen, and homocysteine from B12 depletion, all independent cardiovascular risk factors; multiple meta-analyses demonstrate increased cardiovascular event risk in H. pylori-positive individuals; eradication reduces these inflammatory markers
• Autoimmune thyroid disease: molecular mimicry between H. pylori CagA protein and thyroid antigens is proposed as a mechanism for H. pylori-associated Hashimoto's thyroiditis and Graves' disease; multiple studies demonstrate higher H. pylori prevalence in autoimmune thyroid patients and improvement in antibody titers after eradication in some individuals
• Idiopathic thrombocytopenic purpura (ITP): one of the most robustly documented extra-gastric H. pylori effects; eradication of H. pylori produces durable platelet count normalization in 50 to 70% of ITP patients in high-H. pylori-prevalence populations; the mechanism involves molecular mimicry between H. pylori antigens and platelet surface GPIb and GPIIb-IIIa
• Metabolic effects: H. pylori infection is associated with insulin resistance, altered ghrelin and leptin levels from gastric endocrine cell dysfunction, and increased type 2 diabetes risk in multiple large cohort studies; eradication partially reverses ghrelin dysregulation and metabolic abnormalities
• GERD and medication interactions: H. pylori suppresses gastric acid in patients with corpus-predominant gastritis, meaning that eradication can paradoxically worsen or unmask GERD by restoring gastric acid production; this is clinically important when managing patients with concurrent H. pylori and GERD who require PPI therapy

4. Treatment Protocols and Antibiotic Resistance

5. Confirming Eradication: Why It Is Non-Negotiable

Eradication must be confirmed by stool antigen test or urea breath test at least 4 weeks after completing antibiotic treatment and at least 2 weeks after stopping PPIs. Serum IgG antibodies cannot be used for eradication confirmation because they remain elevated for 12 to 18 months after successful treatment. Treatment failure rates of 15 to 30% from clarithromycin resistance mean that a significant proportion of patients completing a full course of first-line therapy remain infected, accumulating ongoing mucosal damage and cancer risk. Without confirmed eradication, clinical decision-making is compromised and the opportunity for second-line treatment before progressive gastric atrophy develops is lost.

6. Related Lab Tests

7. Clinical Perspective

8. Frequently Asked Questions